Interventions of interest:
- fluticasone furoate and vilanterol (Breo Ellipta®, GSK)
- fluticasone furoate, vilanterol, and umeclidinium (Trelegy Ellipta®, GSK)
ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.
Final Documents
ICER’s President and CEO Sarah K. Emond, MPP stated:
“Over 15 million people in the United States suffer from COPD. Our special report focuses on the medical evidence and value of these two inhalers, specifically for COPD. We recognize that our report will be one of many inputs CMS may consider, and we hope that it will help them as they continue to build a reliable, value-based, transparent drug price negotiation process on behalf of the American people.”
For more information please contact [email protected].
Public Comments
Closed